Linked Life Data

9110055

Source:http://linkedlifedata.com/resource/pubmed/id/9110055

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1997-5-8
pubmed:abstractText
Doxazosin, as a mono-therapy, was studied in 28 patients with mild to severe hypertension over a period of 8 weeks. After a wash-out period of 2 weeks, doxazosin was started at a dose of 1 mg daily and increased gradually until the diastolic blood pressure fell to below 90 mm Hg or a maximum dose of 16 mg daily was reduced. Forty-three percent of the patients had good response with diastolic blood pressure falling to normal (< 90 mm Hg) or by more than 10 mm Hg whilst 68% of the patients had a reduction of greater than 5 mm Hg. Doxazosin reduced blood pressure without significant increase in heart rate and was, overall, well tolerated producing mild side effects not requiring withdrawal, or reduction in dosage of the drug in 6 cases. The effect of doxazosin on lipids showed a trend towards reduction of total cholesterol and increase in HDL, but these data need confirmation in a longer study in a larger population sample.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0309-3913
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
53-9
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Open trial of doxazosin in hypertensive Africans: dose finding, efficacy and safety studies.
pubmed:affiliation
Department of Pharmacology and Therapeutics, University of Ibadan, Nigeria.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial